Table 1 Characteristics of the early RA cohort, at inclusion, 1 and 5 years of follow-up
Characteristics of the early RA cohort† | Inclusiona | 1 year b | 5 years c |
|---|---|---|---|
Female sex n (%) | 152 (71) | 153 (71) | 124 (71) |
Age (years) | 59.9 (14.7) | 61 (14.6) | 64.7 (14.3) |
Symptom duration at inclusion (month); median (IQR) | 7 (5–10) | 7 (5‒10) | 7 (5‒10) |
RF positive % (n) | 61 (132) | 62 (135) | 65 (114) |
Anti-CCP positive % (n) | 56 (104/187) | 58 (108/186) | 59 (90/153) |
RF and/or anti-CCP positive % (n) | 72 (154) | 72 (155) | 75 (132) |
Swollen joints (0-28); median (IQR) | 7 (5–11) | 4 (2‒7) | 4 (4‒7) |
Tender joints (0-28); median (IQR) | 4 (1–9) | 2 (0‒5) | 1 (1‒3) |
DAS28 (0‒10) | 4.64 (1.38) | 3.65 (1.34) | 3.59 (1.38) |
HAQ (0‒3) | 0.85 (0.62) | 0.63 (0.59) | 0.75 (0.66) |
Patient’s global assessment (VAS 0‒100) | 43 (26) | 31 (24) | 35 (24) |
Pain (VAS 0‒100) | 41 (27) | 31 (24) | 30 (23) |
Average grip force right hand (N) | 102 (76) | 131 (85) | 137 (93) |
Average grip force right hand (% of expected) | 39 (25) | 51 (27) | 56 (30) |
Average grip force left hand (N) | 97 (70) | 120 (78) | 130 (88) |
Average grip force left hand (% of expected) | 39 (25) | 49 (27) | 55 (30) |
Methotrexate treatment % (n) | 55 (119) | 63 (137) | 61 (106) |
Other DMARD % (n) | 30 (64) | 31 (67) | 25 (43) |
Corticosteroid treatment % (n) | 39 (83) | 31 (66) | 29 (51) |
CRP (mg/l); median (IQR) | 9 (< 9‒24) | < 9 (< 9‒10) | < 9 < 9‒10) |
ESR (mm/h); median (IQR) | 20 (10–40) | 15 (7‒27) | 16 (10‒25) |